MedKoo product information:

 Irinotecan hydrochloride

irinotecan hydrochloride  is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

CAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution. It is available in two single-dose sizes: 2 mL-fill vials contain 40 mg irinotecan hydrochloride and 5 mL-fill vials contain 100 mg irinotecan hydrochloride. Each milliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, USP. The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid. CAMPTOSAR is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP. Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata or is chemically synthesized.

CLINICAL PHARMACOLOGY

Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. However, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan (see Pharmacokinetics). The precise contribution of SN-38 to the activity of CAMPTOSAR is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form. Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.

  1: Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009 Dec;11(4):710-27. Epub 2009 Oct 27. Review. PubMed PMID: 19859815; PubMed Central PMCID: PMC2782080.

2: Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):243-57. Review. PubMed PMID: 19331590.

3: Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar;18(3):335-48. Review. PubMed PMID: 19243284.

4: Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N, Burman AC. Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem. 2009 Feb;9(2):138-61. Review. PubMed PMID: 19199862.

5: Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review. PubMed PMID: 19147868.

6: Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs. 2008 Dec;9(12):1287-95. Review. PubMed PMID: 19037835.

7: Hatfield JM, Wierdl M, Wadkins RM, Potter PM. Modifications of human carboxylesterase for improved prodrug activation. Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1153-65. Review. PubMed PMID: 18721110; PubMed Central PMCID: PMC2556898.

8: Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des. 2008;14(17):1723-42. Review. PubMed PMID: 18673195.

9: Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol. 2008 Aug;5(8):455-65. Epub 2008 Jun 10. Review. PubMed PMID: 18542119.

10: Strassburg CP, Lankisch TO, Manns MP, Ehmer U. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol. 2008 Jul;82(7):415-33. Epub 2008 May 20. Review. PubMed PMID: 18491077.

11: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

12: Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev. 2008 May 22;60(8):899-914. Epub 2008 Feb 9. Review. PubMed PMID: 18406004.

13: Sai K, Sawada J, Minami H. [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28]. Yakugaku Zasshi. 2008 Apr;128(4):575-84. Review. Japanese. PubMed PMID: 18379174.

14: Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol. 2008;448:63-76. Review. PubMed PMID: 18370231.

15: Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist. 2008 Jan;13(1):39-50. Review. PubMed PMID: 18245011.

16: Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol. 2008 Mar 15;75(6):1262-71. Epub 2007 Oct 22. Review. PubMed PMID: 18061144.

17: Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem. 2007 Nov;7(6):685-709. Review. PubMed PMID: 18045063.

18: Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007 Aug;7(4):216-23. Review. PubMed PMID: 17827442.

19: Sirikantaramas S, Asano T, Sudo H, Yamazaki M, Saito K. Camptothecin: therapeutic potential and biotechnology. Curr Pharm Biotechnol. 2007 Aug;8(4):196-202. Review. PubMed PMID: 17691988.

20: Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62. Review. PubMed PMID: 17691917.

21: Ando Y, Fujita K, Sasaki Y, Hasegawa Y. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther. 2007 Jun;9(3):258-62. Review. PubMed PMID: 17608024.

22: Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007 Aug;50(8):1259-70. Review. PubMed PMID: 17566832.

23: Mladosievicova B, Carter A, Kristova V. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy. Neoplasma. 2007;54(3):181-8. Review. PubMed PMID: 17447847.

24: Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park). 2006 Dec;20(14 Suppl 10):11-9. Review. PubMed PMID: 17354513.

25: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

26: Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des. 2006;12(35):4649-64. Review. PubMed PMID: 17168768.

27: Lenz HJ. Pharmacogenomics and colorectal cancer. Adv Exp Med Biol. 2006;587:211-31. Review. PubMed PMID: 17163168.

28: Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S. Recent progress in target therapy in colorectal cancer. Anticancer Res. 2006 Sep-Oct;26(5B):3973-81. Review. PubMed PMID: 17094429.

29: Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. Review. PubMed PMID: 16990856.

30: Itoh T. [Pharmacokinetic study of cancer chemotherapy]. Yakugaku Zasshi. 2006 Sep;126(9):723-35. Review. Japanese. PubMed PMID: 16946586.

31: Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006 Jul-Aug;11(7):742-52. Review. PubMed PMID: 16880233.

32: Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug;27(8):432-7. Epub 2006 Jul 3. Review. PubMed PMID: 16815558.

33: Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist. 2006 Jun;11(6):602-11. Review. PubMed PMID: 16794239.

34: Borner MM. [Molecular targets in colon cancer]. Ther Umsch. 2006 Apr;63(4):243-8. Review. German. PubMed PMID: 16689454.

35: Tanaka T, Utsunomiya T, Umesaki N. [Prevention of anticancer drug-induced premature ovarian failure]. Nippon Rinsho. 2006 Apr;64 Suppl 4:101-11. Review. Japanese. PubMed PMID: 16689293.

36: Maitland ML, DiRienzo A, Ratain MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10;24(14):2151-7. Review. PubMed PMID: 16682733.

37: Khoukaz T. Administration of anti-EGFR therapy: a practical review. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):20-7. Review. PubMed PMID: 16616283.

38: Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 2005 Apr;1(2):221-34. Review. PubMed PMID: 16555994.

39: Mizutani Y, Nakamura T, Nomoto T, Kawauchi A, Miki T. [Progress in therapy for testicular tumors]. Gan To Kagaku Ryoho. 2006 Feb;33(2):183-7. Review. Japanese. PubMed PMID: 16484853.

40: Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25. Review. PubMed PMID: 16454746.

41: Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother. 2006 Feb;40(2):241-50. Epub 2006 Jan 10. Review. PubMed PMID: 16403849.

42: Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23. Review. PubMed PMID: 16309825.

43: Isomura M, Miki Y. [SNPs associated with adverse effects]. Gan To Kagaku Ryoho. 2005 Nov;32(12):1908-13. Review. Japanese. PubMed PMID: 16282725.

44: Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75. Epub 2005 Nov 3. Review. PubMed PMID: 16271446.

45: Sugimoto Y. [Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents]. Seikagaku. 2005 Sep;77(9):1196-200. Review. Japanese. PubMed PMID: 16241009.

46: Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005 Oct;6(10):780-9. Review. PubMed PMID: 16198984.

47: Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005 Jul;19(8):1057-63; discussion 1063-4, 1069. Review. PubMed PMID: 16131047.

48: Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 2005 Nov 1;13(21):5892-908. Review. PubMed PMID: 16129603.

49: Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer. 2005 Jul;5(2):132-5. Review. PubMed PMID: 16098255.

50: Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology (Williston Park). 2005 Apr;19(5):589-95. Review. PubMed PMID: 15945340.

51: Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S19-27. Review. PubMed PMID: 15871762.

52: Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. Review. PubMed PMID: 15821783.

53: Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. Review. PubMed PMID: 15762770.

54: Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev. 2005;37(1):41-213. Review. PubMed PMID: 15747500.

55: Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005 Feb;10(2):104-11. Review. PubMed PMID: 15709212.

56: de Chaisemartin L, Loriot MA. [Pharmacogenetics of anticancer drugs.]. Pathol Biol (Paris). 2005 Mar;53(2):116-24. Review. French. PubMed PMID: 15708657.

57: Toffoli G, Cecchin E. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. J Chemother. 2004 Nov;16 Suppl 4:31-5. Review. PubMed PMID: 15688606.

58: Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother. 2004 Nov;16 Suppl 4:25-30. Review. PubMed PMID: 15688605.

59: Miki T, Mikami K, Mizutani Y. [The second-line chemotherapy for urological cancers]. Gan To Kagaku Ryoho. 2005 Jan;32(1):33-8. Review. Japanese. PubMed PMID: 15675579.

60: Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. Review. PubMed PMID: 15494600.

61: Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics. 2004 Oct;5(7):835-43. Review. PubMed PMID: 15469406.

62: Sternberg CN, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs. 2004;8 Suppl 1:S4-15. Review. PubMed PMID: 15341878.

63: Tedesco KL, Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol. 2004 Oct;5(5):393-403. Review. PubMed PMID: 15341677.

64: Yang S, Zhang WN. [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I]. Yao Xue Xue Bao. 2004 May;39(5):396-400. Review. Chinese. PubMed PMID: 15338888.

65: Schöffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004 Feb;15(2):85-106. Review. PubMed PMID: 15075664.

66: Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004 Mar;56(1):53-102. Review. PubMed PMID: 15001663.

67: Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. Review. PubMed PMID: 14743888.

68: Baba H, Kakeji Y, Oki E, Tokunaga E, Ushiro S, Watanabe M, Maehara Y. [Chemotherapy for gastric cancer]. Gan To Kagaku Ryoho. 2003 Nov;30(12):1881-8. Review. Japanese. PubMed PMID: 14650954.

69: Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003 Oct 20;22(47):7296-304. Review. PubMed PMID: 14576839.

70: Matsui A, Okuda M, Tsujitsuka K, Enomoto K, Maruyama K. Pharmacology of intraperitoneal CPT-11. Surg Oncol Clin N Am. 2003 Jul;12(3):795-811, xv. Review. PubMed PMID: 14567032.

71: Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6 Suppl 1:2-8. Review. PubMed PMID: 12775012.

72: Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. Review. PubMed PMID: 12769780.

73: Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single-agent and combination phase I study overview. Semin Oncol. 2002 Dec;29(6 Suppl 18):18-23. Review. PubMed PMID: 12571806.

74: Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002 Aug;16(4):253-62. Review. PubMed PMID: 12570013.

75: Geffen DB, Man S. New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. Review. PubMed PMID: 12516906.

76: Kato Y, Suzuki H, Sugiyama Y. Toxicological implications of hepatobiliary transporters. Toxicology. 2002 Dec 27;181-182:287-90. Review. PubMed PMID: 12505327.

77: Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol. 2003 Jan;45(1):91-108. Review. PubMed PMID: 12482574.

78: Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002 Dec;13(12):1841-51. Review. PubMed PMID: 12453851.

79: McMullen KP, Blackstock AW. Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer. 2002 May;2(1):24-30. Review. PubMed PMID: 12453333.

80: Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 2002 Oct;29(5 Suppl 14):55-60. Review. PubMed PMID: 12422314.

81: Berlin JD. Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):13-5. Review. PubMed PMID: 12199627.

82: Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets. 2002 Jun;2(2):103-23. Review. PubMed PMID: 12188913.

83: Furue H. [Prevention of side reactions--present status and problems--special references]. Gan To Kagaku Ryoho. 2002 Jul;29(7):1325-30. Review. Japanese. PubMed PMID: 12146019.

84: Sandler A. Irinotecan therapy for small-cell lung cancer. Oncology (Williston Park). 2002 Apr;16(4):419-25, 428, 433; discussion 433-4, 437-8. Review. PubMed PMID: 12017533.

85: Jung LL, Zamboni WC. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist Updat. 2001 Aug;4(4):273-88. Review. PubMed PMID: 11998845.

86: Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging. 2002;19(2):85-100. Review. PubMed PMID: 11950376.

87: Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002 Mar;8(3):641-61. Review. PubMed PMID: 11895891.

88: Palumbo M, Sissi C, Gatto B, Moro S, Zagotto G. Quantitation of camptothecin and related compounds. J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):121-40. Review. PubMed PMID: 11817024.

89: McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001;61(15):2309-26. Review. PubMed PMID: 11772141.

90: Jung LL, Zamboni WC. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist Updat. 2001 Jun;4(3):152-67. Review. Corrected and republished in: Drug Resist Updat. 2001 Aug;4(4):273-88. PubMed PMID: 11768329.

91: Bomgaars L, Berg SL, Blaney SM. The development of camptothecin analogs in childhood cancers. Oncologist. 2001;6(6):506-16. Review. PubMed PMID: 11743213.

92: Bécouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001 Dec;40(3):265-72. Review. PubMed PMID: 11738949.

93: da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol. 2001 Aug;1(4):364-9. Review. PubMed PMID: 11710734.

94: Huang CH, Treat J. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology. 2001;61 Suppl 1:14-24. Review. PubMed PMID: 11598410.

95: Inoue A, Saijo N. Recent advances in the chemotherapy of non-small cell lung cancer. Jpn J Clin Oncol. 2001 Jul;31(7):299-304. Review. PubMed PMID: 11518741.

96: Grivicich I, Mans DR, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res. 2001 Sep;34(9):1087-103. Review. PubMed PMID: 11514832.

97: Shih C, Teicher BA. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des. 2001 Sep;7(13):1259-76. Review. PubMed PMID: 11472266.

98: Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24(5):353-67. Review. PubMed PMID: 11419562.

99: Mross K, Semsek D. [Chemotherapy of colonic carcinoma in the year 2001]. Praxis (Bern 1994). 2001 Mar 22;90(12):497-510. Review. German. PubMed PMID: 11324309.

100: Berlin J. New directions in the treatment of advanced colorectal cancer. Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):27-30. Review. PubMed PMID: 11301837.

101: Royce ME, Hoff PM, Pazdur R. Novel oral chemotherapy agents. Curr Oncol Rep. 2000 Jan;2(1):31-7. Review. PubMed PMID: 11122822.

102: Kobayashi K, Kobayashi T. [Outpatient clinic in Saitama Cancer Center]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1656-61. Review. Japanese. PubMed PMID: 11057315.

103: Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf. 2000 Oct;23(4):255-78. Review. PubMed PMID: 11051215.

104: Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol. 2000 Oct;35(4):385-402. Review. PubMed PMID: 11025469.

105: Baba H, Kohnoe S, Endo K, Ikeda Y, Toh Y, Nakashima H, Okamura T. [State of the treatment for gastrointestinal cancer]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1233-46. Review. Japanese. PubMed PMID: 10945022.

106: Nakao M, Nomoto T, Mizutani Y, Miki T. [Salvage chemotherapy in refractory testicular cancer]. Gan To Kagaku Ryoho. 2000 Apr;27(4):542-7. Review. Japanese. PubMed PMID: 10790996.

107: Iyer L. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Mol Diagn. 1999 Dec;4(4):327-33. Review. PubMed PMID: 10671643.

108: Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem. 2000 Jan;7(1):39-58. Review. PubMed PMID: 10637356.

109: Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol. 1999 Dec;26(6):647-62. Review. PubMed PMID: 10606258.

110: Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):39-46. Review. PubMed PMID: 10550825.

111: Crystal RG. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol. 1999;43 Suppl:S90-9. Review. PubMed PMID: 10357566.

112: Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol. 1999;125(3-4):134-40. Review. PubMed PMID: 10235466.

113: Cragg GM, Newman DJ. Discovery and development of antineoplastic agents from natural sources. Cancer Invest. 1999;17(2):153-63. Review. PubMed PMID: 10071600.

114: Taguchi T. [Gastrointestinal cancer and oral anticancer agents]. Gan To Kagaku Ryoho. 1999 Feb;26(3):284-94. Review. Japanese. PubMed PMID: 10065090.

115: Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. [Clinical activity spectrum of irinotecan]. Bull Cancer. 1998 Dec;Spec No:21-5. Review. French. PubMed PMID: 9932080.

116: Allen M, Cunningham D, Schmitt C. The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. Anticancer Drugs. 1998 Oct;9(9):783-90. Review. PubMed PMID: 9840724.

117: Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. Review. PubMed PMID: 9834817.

118: Arbuck SG, Takimoto CH. An overview of topoisomerase I-targeting agents. Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12. Review. PubMed PMID: 9779876.

119: Herben VM, Ten Bokkel Huinink WW, Schellens JH, Beijnen JH. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharm World Sci. 1998 Aug;20(4):161-72. Review. PubMed PMID: 9762728.

120: Vassal G, Pondarré C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 1998 Mar;80(3):271-80. Review. PubMed PMID: 9615866.

121: Armand JP. New anticancer drugs in Europe. Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:70-93. Review. PubMed PMID: 9210890.

122: Furukawa M, Harada T, Tanaka T, Kuwano M. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance]. Nippon Rinsho. 1997 May;55(5):1096-102. Review. Japanese. PubMed PMID: 9155159.

123: Cragg GM, Newman DJ, Weiss RB. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol. 1997 Apr;24(2):156-63. Review. PubMed PMID: 9129686.

124: Nishio K, Arioka H, Saijo N. [Apoptosis and chemosensitivity]. Gan To Kagaku Ryoho. 1997 Jan;24(2):216-21. Review. Japanese. PubMed PMID: 9030234.

125: Mani S, Ratain MJ. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov;8(6):525-34. Review. PubMed PMID: 8971473.

126: Hanauske AR. The development of new chemotherapeutic agents. Anticancer Drugs. 1996 Aug;7 Suppl 2:29-32. Review. PubMed PMID: 8862708.

127: Torck M, Pinkas M. [Camptothecin and derivatives: a new class of antitumor agents]. J Pharm Belg. 1996 Jul-Aug;51(4):200-7. Review. French. PubMed PMID: 8965250.

128: Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol. 1996 Feb;23(1 Suppl 3):34-41. Review. PubMed PMID: 8633252.

129: Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol. 1996 Feb;23(1 Suppl 3):3-10. Review. PubMed PMID: 8633251.

130: Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer. 1996;32A Suppl 3:S1-8. Review. PubMed PMID: 8943658.

131: Verweij J. New promising anticancer agents in development: what comes next? Cancer Chemother Pharmacol. 1996;38 Suppl:S3-10. Review. PubMed PMID: 8765408.

132: Terada K. [Development of new anti-cancer agents in Europe]. Gan To Kagaku Ryoho. 1996 Jan;23(2):231-7. Review. Japanese. PubMed PMID: 8611052.

133: Fukuoka M. [Current status and problems in clinical trial for new anticancer drug in Japan]. Gan To Kagaku Ryoho. 1996 Jan;23(2):141-5. Review. Japanese. PubMed PMID: 8611040.

134: Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Dec;9(12):1321-8; 1331; discussion 1332-4. Review. PubMed PMID: 8771106.

135: Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Nov;9(11):1191-9. Review. PubMed PMID: 8703688.

136: Saijo N. [Strategies for the overcoming of drug resistance]. Gan To Kagaku Ryoho. 1995 Feb;22(3):371-81. Review. Japanese. PubMed PMID: 7880108.

137: Masuda N. [Phase III trial of new anticancer agents from a medical oncologists viewpoint]. Gan To Kagaku Ryoho. 1995 Feb;22(3):313-8. Review. Japanese. PubMed PMID: 7880100.

138: Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs. 1995 Jan;49(1):11-9. Review. PubMed PMID: 7705211.

139: Ariyoshi Y, Sugiura T. [New promising anticancer drugs for lung cancer]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2578-84. Review. Japanese. PubMed PMID: 7979416.

140: Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y, et al. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol. 1994;34 Suppl:S112-7. Review. PubMed PMID: 8070019.

141: Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. New anticancer agents. Cancer Chemother Biol Response Modif. 1994;15:130-51. Review. PubMed PMID: 7779583.

142: Shinkai T, Saijo N. [Phase II clinical trials in patients with lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi. 1993 Dec;31 Suppl:232-44. Review. Japanese. PubMed PMID: 8007470.

143: Tsukagoshi S. [Recent development of new anticancer drugs in Japan]. Nippon Rinsho. 1993 Jul;51(7):1923-9. Review. Japanese. PubMed PMID: 8103565.

144: Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993 Feb 17;85(4):271-91. Review. PubMed PMID: 8381186.

145: Furue H. [Topoisomerase inhibitors developing in Japan]. Gan To Kagaku Ryoho. 1993 Jan;20(1):42-9. Review. Japanese. PubMed PMID: 8422186.